Jan Snoeys

5.5k total citations · 2 hit papers
94 papers, 3.7k citations indexed

About

Jan Snoeys is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Jan Snoeys has authored 94 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 30 papers in Molecular Biology and 30 papers in Pharmacology. Recurrent topics in Jan Snoeys's work include Drug Transport and Resistance Mechanisms (33 papers), Pharmacogenetics and Drug Metabolism (27 papers) and Drug-Induced Hepatotoxicity and Protection (12 papers). Jan Snoeys is often cited by papers focused on Drug Transport and Resistance Mechanisms (33 papers), Pharmacogenetics and Drug Metabolism (27 papers) and Drug-Induced Hepatotoxicity and Protection (12 papers). Jan Snoeys collaborates with scholars based in Belgium, United States and United Kingdom. Jan Snoeys's co-authors include Frank Jacobs, Mario Monshouwer, Bart De Geest, Joke Lievens, Neil Parrott, Ming Zheng, Yuan Chen, Vijay Upreti, Tycho Heimbach and S D Hall and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Blood.

In The Last Decade

Jan Snoeys

91 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease

2016 517 citations Frank Jacobs, Jan Snoeys et al. profile →
Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective

2015 358 citations Jan Snoeys et al. Clinical Pharmacology & Therapeutics profile →

Peers

Countries citing papers authored by Jan Snoeys

Since Specialization

Citations

This map shows the geographic impact of Jan Snoeys's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Snoeys with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Snoeys more than expected).

Fields of papers citing papers by Jan Snoeys

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Snoeys. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Snoeys. The network helps show where Jan Snoeys may publish in the future.

Co-authorship network of co-authors of Jan Snoeys

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Snoeys. A scholar is included among the top collaborators of Jan Snoeys based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Snoeys. Jan Snoeys is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Absorption, distribution, metabolism, and excretion of an antiviral drug-Fc conjugate CD388 following subcutaneous administration of 14C-CD388 in the rat 2025 ·Drug Metabolism and Disposition ·Annouschka Laenen, (unknown), Grayson Hough, Jan Snoeys, Filip Cuyckens, Geert Mannens, Stephen Harris, Voon Ong	0
2	CYP3A4-Mediated Bioactivation of the β-Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor JNJ-54861911 Results in Redox-Neutral Addition of Glutathione via Catalysis by Glutathione S-Transferase α1, Identified as the Major Target Protein in Human Hepatocytes 2024 ·Chemical Research in Toxicology ·(unknown), (unknown), (unknown), Pieter Verboven, Filip Cuyckens, (unknown), (unknown), Dean J. Naisbitt, Megan S. Ford, Xiaoli Meng, Shingo Sakamoto, Tamio Fukushima, Jan Snoeys	2
3	Therapeutic siRNA Loaded to RISC as Single and Double Strands Requires an Appropriate Quantitative Assay for RISC PK Assessment 2024 ·Nucleic Acid Therapeutics ·Rui Xu, Emmanuel Njumbe Ediage, Tom Verhaeghe, Jan Snoeys, Lieve Dillen	3
4	Development of 4‐Pyridoxic Acid PBPK Model to Support Biomarker‐Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease 2023 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), Jan Snoeys, Hong Shen, Amin Rostami‐Hodjegan, Daniel Scotcher, Aleksandra Galetin	14
5	Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B 2023 ·CPT Pharmacometrics & Systems Pharmacology ·Shinji Nakayama, Kota Toshimoto, Shinji Yamazaki, Jan Snoeys, Yuichi Sugiyama	3
6	Intestinal organoids as an in vitro platform to characterize disposition, metabolism, and safety profile of small molecules 2023 ·European Journal of Pharmaceutical Sciences ·Stephanie Schulz, (unknown), (unknown), (unknown), Marjolein van Heerden, Pieter Verboven, (unknown), (unknown), (unknown), Annett Kunze, (unknown), (unknown), René Overmeer, (unknown), Robert G.J. Vries, Sylvia F. Boj, Mario Monshouwer, Farzin Pourfarzad, Jan Snoeys	19
7	Increased bioavailability of a P-gp substrate: Co-release of etoposide and zosuquidar from amorphous solid dispersions 2023 ·International Journal of Pharmaceutics ·(unknown), (unknown), René Holm, (unknown), Jan Snoeys, Ulla Gro Nielsen, Ingunn Tho, Carsten Uhd Nielsen	4
8	Combinational Inhibition of P-Glycoprotein-Mediated Etoposide Transport by Zosuquidar and Polysorbate 20 2023 ·Pharmaceutics ·(unknown), René Holm, (unknown), Jan Snoeys, Ulla Gro Nielsen, Carsten Uhd Nielsen	3
9	Identification of novel inhibitors of rat Mrp3 2021 ·European Journal of Pharmaceutical Sciences ·(unknown), Christophe Buyck, (unknown), Bing Qi, (unknown), Herman van Vlijmen, Jan Snoeys, Eef Hoeben, An Vermeulen, Pieter Annaert	2
10	Oral etoposide and zosuquidar bioavailability in rats: Effect of co-administration and in vitro-in vivo correlation of P-glycoprotein inhibition 2021 ·International Journal of Pharmaceutics X ·(unknown), René Holm, (unknown), Jan Snoeys, Ulla Gro Nielsen, Carsten Uhd Nielsen	8
11	Short-term supplementation of celecoxib-shifted butyrate production on a simulated model of the gut microbial ecosystem and ameliorated in vitro inflammation 2020 ·npj Biofilms and Microbiomes ·Emma Hernandez‐Sanabria, (unknown), Marta Calatayud, Ruben Props, Laurent Leclercq, Jan Snoeys, Tom Van de Wiele	26
12	Insight into the colonic disposition of celecoxib in humans 2020 ·European Journal of Pharmaceutical Sciences ·(unknown), Joachim Brouwers, Jan Snoeys, Patrick Augustijns, Tim Vanuytsel	16
13	Montmorillonite-surfactant hybrid particles for modulating intestinal P-glycoprotein-mediated transport 2019 ·International Journal of Pharmaceutics ·(unknown), Ariane Kahnt, Lieve Dillen, (unknown), Jan Snoeys, Ulla Gro Nielsen, René Holm, Carsten Uhd Nielsen	12
14	Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug–Drug Interactions 2018 ·Clinical Pharmacokinetics ·Annett Kunze, Emmanuel Njumbe Ediage, Lieve Dillen, Mario Monshouwer, Jan Snoeys	79
15	Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury 2017 ·Toxicological Sciences ·Monicah A. Otieno, Jan Snoeys, Wing Lam, (unknown), Mark R. Player, Alessandro Pocai, Rhys Salter, Damir Simic, Hollie S. Skaggs, Bhanu Singh, Heng‐Keang Lim	66
16	Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling 2016 ·Clinical Pharmacokinetics ·Jan Snoeys, Maria Beumont, Mario Monshouwer, Sivi Ouwerkerk‐Mahadevan	8
17	Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir 2015 ·Clinical Pharmacokinetics ·Sivi Ouwerkerk‐Mahadevan, Jan Snoeys, Monika Peeters, Maria Beumont‐Mauviel, Alexandru Simion	63
18	Apolipoprotein A-I and lecithin:cholesterol acyltransferase transfer induce cholesterol unloading in complex atherosclerotic lesions 2009 ·Gene Therapy ·Eline Van Craeyveld, Joke Lievens, Frank Jacobs, Yingmei Feng, Jan Snoeys, Bart De Geest	20
19	Species Differences in Hepatocyte-Directed Gene Transfer: Implications for Clinical Translation 2009 ·Current Gene Therapy ·Frank Jacobs, Yingmei Feng, Eline Van Craeyveld, Joke Lievens, Jan Snoeys, Bart De Geest	6
20	Direct comparison of hepatocyte-specific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer 2008 ·Gene Therapy ·Frank Jacobs, Jan Snoeys, Yingmei Feng, Eline Van Craeyveld, Joke Lievens, Donna Armentano, Shuk Han Cheng, Bart De Geest	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact